• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动脉内应用纤溶酶原联合经皮腔内血管成形术(PTA)或导管辅助溶栓(CL)治疗下肢慢性周围血管闭塞性疾病(POL)的有效性。

Effectiveness of intraarterial plasminogen application in combination with percutaneous transluminal angioplasty (PTA) or catheter assisted lysis (CL) in patients with chronic peripheral occlusive disease of the lower limbs (POL).

作者信息

Tilsner V, Witte G

机构信息

Abt. für Blutgerinnungsstörungen, Universitätsklinik, Hamburg-Eppendorf, FRG.

出版信息

Haemostasis. 1988;18 Suppl 1:139-56. doi: 10.1159/000215849.

DOI:10.1159/000215849
PMID:2965085
Abstract

The accepted correct procedure for treating occlusive arterial diseases includes surgical disobstruction, CL as well as PTA. Combined non-surgical strategies are effective in about 60% of these patients. However, a high risk of rethrombosis despite from the prophylaxis with anticoagulants like heparin or antiplatelet drugs like ASA is proven, especially in patients with multi-segmental stenosis as well as in patients with extensive narrowing of the arteries. In these cases primary lesions (endangitis obliterans) or secondary lesions of the endothelium cause local depletion of plasminogen in the endothelium. Independent of the method used for reopening the vessel in these patients, a significant progression of the vessel disease and a high rethrombosis rate during longterm follow-up is observed. These results lead us to apply plasminogen locally to decrease the rate of rethrombosis. In patients suffering from stage III-IV (La Fontaine) including patients with multi-segmental stenosis as well as extended narrowing of the artery, PTA in combination with CL was performed. The catheter was placed as near as possible to the thrombus. In some cases the 'fibrinolyticum' could be injected directly into the thrombus. In these cases a bolus of 4,000 U/ml was locally infused, otherwise 1.0-1.5 million U urokinase per 24 hrs. were locally infused with heparin. In 28% (22 patients) no sufficient clinical response occurred using this combined therapy and plasminogen was applied locally. The following criteria supported our decision to include the patients in this study: 1. Insufficient response occurring after 12-24 hrs. of local infusion. 2. Following 6 bolus injections no reopening of the vessel occured within 60 minutes or the clinical response was insufficient due to rethrombosis. 3. Insufficient effects of lysis therapy after 2 hours and contraindication for a systemic fibrinolytic therapy (e.g. hypertension, age, etc.). 1,000 U plasminogen per ml were infused locally or 2,000 U up to 5,000 U plasminogen (in 5 to 10 ml 0.9% saline) were infused slowly (2-4 minutes infusion time) into the catheter in these patients 10 minutes after unsuccessful treatment with local urokinase therapy. Five minutes after administering plasminogen local intraarterial fibrinolytic therapy with urokinase was continued. No severe side effects due to this therapy were observed, although some patients suffered from acute pains in the peripheral segments of the arteries occurring immediately after infusion of plasminogen. In 16 of 22 patients a complete recanalization occurred and in 3 patients a satisfying clinical improvement was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

治疗闭塞性动脉疾病公认的正确程序包括手术疏通、腔内激光治疗(CL)以及经皮腔内血管成形术(PTA)。联合非手术策略在约60%的此类患者中有效。然而,已证实尽管使用肝素等抗凝剂或阿司匹林等抗血小板药物进行预防,但再血栓形成的风险仍然很高,尤其是在多节段狭窄患者以及动脉广泛狭窄的患者中。在这些情况下,原发性病变(血栓闭塞性脉管炎)或内皮的继发性病变会导致内皮中纤溶酶原局部耗竭。无论在这些患者中使用何种方法重新开通血管,在长期随访中都观察到血管疾病的显著进展和高再血栓形成率。这些结果促使我们局部应用纤溶酶原以降低再血栓形成率。对于患有III-IV期(拉方丹分期)的患者,包括多节段狭窄以及动脉广泛狭窄的患者,进行了PTA联合CL治疗。将导管尽可能靠近血栓放置。在某些情况下,“纤维蛋白溶解剂”可直接注入血栓中。在这些情况下,局部注入4000 U/ml的大剂量药物,否则每24小时局部注入100 - 150万U尿激酶并联合肝素。在28%(22例患者)中,使用这种联合治疗未出现足够的临床反应,于是局部应用纤溶酶原。以下标准支持我们将这些患者纳入本研究的决定:1. 局部输注12 - 24小时后反应不足。2. 在6次大剂量注射后,60分钟内血管未重新开通,或者由于再血栓形成临床反应不足。3. 溶栓治疗2小时后效果不佳且存在全身溶栓治疗的禁忌证(如高血压、年龄等)。在局部尿激酶治疗失败10分钟后,向这些患者的导管内局部输注每毫升1000 U纤溶酶原,或缓慢(输注时间2 - 4分钟)注入2000 - 5000 U纤溶酶原(溶于5 - 10 ml 0.9%盐水中)。在给予纤溶酶原5分钟后,继续用尿激酶进行局部动脉内溶栓治疗。尽管一些患者在注入纤溶酶原后立即出现动脉外周段急性疼痛,但未观察到该治疗引起的严重副作用。22例患者中有16例实现了完全再通,3例患者观察到临床状况有令人满意的改善。(摘要截断于400字)

相似文献

1
Effectiveness of intraarterial plasminogen application in combination with percutaneous transluminal angioplasty (PTA) or catheter assisted lysis (CL) in patients with chronic peripheral occlusive disease of the lower limbs (POL).动脉内应用纤溶酶原联合经皮腔内血管成形术(PTA)或导管辅助溶栓(CL)治疗下肢慢性周围血管闭塞性疾病(POL)的有效性。
Haemostasis. 1988;18 Suppl 1:139-56. doi: 10.1159/000215849.
2
[Intraarterial urokinase infusion therapy for arterial occlusive disease of the pelvis and extremities with special reference to short-term high dose infusion].
Nihon Igaku Hoshasen Gakkai Zasshi. 1990 Mar 25;50(3):229-39.
3
[Results of in situ arterial thrombolysis by the combination of urokinase and lysyl plasminogen in acute arterial occlusive diseases of the lower limbs].[尿激酶与赖氨酰纤溶酶原联合应用于下肢急性动脉闭塞性疾病的原位动脉溶栓结果]
J Radiol. 1985 May;66(5):385-91.
4
[Intra-arterial thrombolytic therapy of lower limb ischemia].[下肢缺血的动脉内溶栓治疗]
Bull Acad Natl Med. 1990 Feb;174(2):197-207; discussion 207-9.
5
Percutaneous transluminal angioplasty of crural arteries.下肢动脉经皮腔内血管成形术
Acta Radiol. 1992 Mar;33(2):152-5.
6
Catheter-lysis: indications and primary results.导管溶栓术:适应证及初步结果
Int Angiol. 1985 Jan-Mar;4(1):117-23.
7
LYS-plasminogen shortens the duration of local thrombolytic treatment of peripheral arterial occlusions--a randomized controlled trial.赖氨酸纤溶酶原缩短外周动脉闭塞局部溶栓治疗的持续时间——一项随机对照试验。
Wien Klin Wochenschr. 1999 Jan 15;111(1):21-5.
8
Acute peripheral arterial and graft occlusion: treatment with selective infusion of urokinase and lysyl plasminogen.
Radiology. 1986 Feb;158(2):481-5. doi: 10.1148/radiology.158.2.3941877.
9
Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study.静脉注射阿昔单抗、动脉内注射重组组织型纤溶酶原激活剂(rtPA)以及额外的经皮腔内血管成形术(PTA)/支架置入术的积极治疗可改善急性椎基底动脉闭塞的临床结局:急性椎基底动脉卒中治疗中局部纤溶与静脉注射阿昔单抗联合应用(FAST):一项多中心研究的结果
Stroke. 2005 Jun;36(6):1160-5. doi: 10.1161/01.STR.0000165918.80812.1e. Epub 2005 May 12.
10
Peripheral artery thrombolysis with urokinase-lys-plasminogen. A disappointing experience.
Int Angiol. 1987 Apr-Jun;6(2):183-6.

引用本文的文献

1
Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings.
Neuroradiology. 1996 Feb;38(2):181-5. doi: 10.1007/BF00604816.